Latest imported 13F data

Carlyle Group Inc.

Rob Citrone•CIK: 1527166•Filing: Q4 2025

Carlyle Group, managed by Rob Citrone, holds a concentrated portfolio with 66.7% in MDLN, reflecting a high-conviction strategy. Recent moves include adding QTTB and PHAT, while significantly cutting SPRB and XCUR, showcasing a dynamic approach to capitalizing on market opportunities.

Total AUM
$13.6B
QoQ Performance
+212.8%
Positions
20
Top 10 Concentration
99.9%
Latest Filing
Q4 2025

Top Holdings Allocation

MDLN
SARO
MDLN66.7%
SARO32.3%
PHAT0.4%
PONY0.3%
INVH0.1%
GETY0.1%
CUBE0.1%
QTTB0.0%

📈 Biggest Buys

MDLN
Medline Inc
NEW
66.7% of portfolio
INVH
Invitation Homes Inc
+39.1%
0.1% of portfolio
ACET
Adicet Bio Inc
NEW
0.0% of portfolio
HOOD
Robinhood Mkts Inc
NEW
0.0% of portfolio
SYRE
Spyre Therapeutics Inc
NEW
0.0% of portfolio

📉 Biggest Sells

SPRB
Spruce Biosciences Inc
-98.7%
0.0% of portfolio
SPWR
SunPower Inc
-65.6%
0.0% of portfolio
XCUR
Exicure Inc
-80.0%
0.0% of portfolio

Sector Breakdown

Other100.0%

🚪 Exited Positionssold since Q3 2025

TORCEUR
Adicet Bio Inc
SOLD
$2.4M

Changes from Q3 2025

NEW4 new positions
↑1 increased
↓3 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022

📌 Top Holdings

MDLN66.7%
Medline Inc
$9.0B
SARO32.3%
Standardaero Inc
$4.4B
PHAT0.4%
Phathom Pharmaceuticals Inc
$58.0M
PONY0.3%
Pony Ai Inc
$34.3M
INVH0.1%
Invitation Homes Inc
$18.5M

⚖️ Compare Fund

Compare this fund's holdings with other hedge funds.

🎯 Fund Movement Signals

See AI-analyzed fund movement signals and accumulation patterns.

👤 Insider Trading

See what corporate insiders are buying and selling.